What is the Return on Assets (ROA) of Karo Pharma this year?
The Return on Assets (ROA) of Karo Pharma is -0 undefined this year.
Karo Pharma ROA 2024
Karo Pharma ROA
-0
Ticker
KARO.ST
ISIN
SE0007464888
WKN
A14YW4
In 2024, Karo Pharma's return on assets (ROA) was -0, a 0% increase from the 0 ROA in the previous year.
Karo Pharma Aktienanalyse
What does Karo Pharma do?
Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROA Details
Understanding Karo Pharma's Return on Assets (ROA)
Karo Pharma's Return on Assets (ROA) is a key performance indicator that measures the company's profitability in relation to its total assets. It is calculated by dividing the net income by the total assets. A higher ROA indicates efficient asset utilization to generate profits, reflecting managerial effectiveness and financial health.
Year-to-Year Comparison
Comparing Karo Pharma's ROA year-over-year provides insights into the company’s operational efficiency and asset utilization trends. An increasing ROA demonstrates enhanced asset efficiency and profitability, while a declining ROA can indicate operational or financial challenges.
Impact on Investments
Investors consider Karo Pharma's ROA as a crucial metric to evaluate the company’s profitability and efficiency. A higher ROA signifies that the company is effectively utilizing its assets to generate profits, making it a potentially attractive investment.
Interpreting ROA Fluctuations
Variations in Karo Pharma’s ROA can be attributed to changes in net income, asset purchases, or operational efficiencies. Analyzing these fluctuations assists in assessing the company's financial performance, management efficiency, and strategic financial positioning.
Frequently Asked Questions about Karo Pharma stock
What was the ROA of Karo Pharma compared to the previous year?
The ROA of Karo Pharma has increased by 0% compared to the previous year.
What consequences do high ROA have for investors of Karo Pharma?
A high ROA is advantageous for investors of Karo Pharma, as it indicates that the company efficiently utilizes its assets and generates good profits.
What are the consequences of low ROA for investors in Karo Pharma?
A low ROA can be unfavorable for investors of Karo Pharma as it indicates that the company is inefficiently utilizing its assets and may potentially achieve lower profits.
How does an increase in the ROA of Karo Pharma affect the company?
An increase in ROA of Karo Pharma can be an indicator of improved efficiency in asset utilization and higher profitability.
How does a reduction in ROA of Karo Pharma impact the company?
A reduction in the ROA of Karo Pharma can be an indicator of lower asset efficiency and profitability.
What are some factors that can influence the ROA of Karo Pharma?
Some factors that can influence the ROA of Karo Pharma include revenue, operating costs, asset structure, and industry average.
Why is the ROA of Karo Pharma important for investors?
The ROA of Karo Pharma is important for investors as it is an indicator of the company's profitability and efficiency in utilizing assets. It provides investors with information on how well the company utilizes its resources to generate profits.
What strategic measures can Karo Pharma take to improve ROA?
To improve ROA, Karo Pharma can take measures such as cost savings, revenue growth, optimizing asset structure, and diversifying its business activities. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic measures to improve ROA.
How much dividend does Karo Pharma pay?
Over the past 12 months, Karo Pharma paid a dividend of 0.27 SEK . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Karo Pharma is expected to pay a dividend of 0.4 SEK.
What is the dividend yield of Karo Pharma?
The current dividend yield of Karo Pharma is 0.45 %.
When does Karo Pharma pay dividends?
Karo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Karo Pharma?
Karo Pharma paid dividends every year for the past 4 years.
What is the dividend of Karo Pharma?
For the upcoming 12 months, dividends amounting to 0.4 SEK are expected. This corresponds to a dividend yield of 0.66 %.
In which sector is Karo Pharma located?
Karo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Karo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Karo Pharma from 5/11/2018 amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.
When did Karo Pharma pay the last dividend?
The last dividend was paid out on 5/11/2018.
What was the dividend of Karo Pharma in the year 2023?
In the year 2023, Karo Pharma distributed 0 SEK as dividends.
In which currency does Karo Pharma pay out the dividend?
The dividends of Karo Pharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Karo Pharma
Our stock analysis for Karo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
